Close
FINDING CURES TOGETHER<sup>SM</sup>

News Releases

 

 

AACR Accepting Calls for Nominations for 2016 Team Science Award16298667/30/2015 7:52:35 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx746False2015-07-30T17:00:00Z<div class="ExternalClass95676E5A71CA4545BEF45D10CEEE8B12"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) is accepting nominations for the 2016 AACR Team Science Award.</p><p>The <a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=8">AACR Team Science Award</a>, now in its 10th year, recognizes an outstanding interdisciplinary research team for its innovative and meritorious scientific work that has advanced, or will likely advance cancer research, detection, diagnosis, prevention, or treatment. </p><p>The winning team will be recognized at the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=63">AACR Annual Meeting 2016</a>, to be held April 16-20, in New Orleans, and will collectively receive a $50,000 prize, generously supported by grants from Eli Lilly and Company.</p><p>The 2015 award recognized the <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=689">Designing AR Inhibitors Team</a> for their collective work in discovering and developing the novel antiandrogen enzalutamide (Xtandi) for the treatment of metastatic castration-resistant prostate cancer. The team was comprised of Charles Sawyers, MD, PhD, team leader, director of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center; Howard Scher, MD, chief of genitourinary oncology service at Memorial Sloan Kettering; and Michael Jung, PhD, distinguished professor in the Department of Chemistry and Biochemistry at the University of California, Los Angeles.</p><ul><li>Deadline for nominations&#58; Aug. 5, 2015</li><li><a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=8">Review the award information</a> or&#160;contact Monique P. Eversley at <a href="mailto&#58;awards@aacr.org">awards@aacr.org</a> to learn more. </li></ul></div>
Nominations Open for 2016 AACR-CRI Lloyd J. Old Award in Cancer Immunology16292917/30/2015 6:13:49 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx745False2015-07-30T16:00:00Z<div class="ExternalClass2BF5AD0FF6EB4FC68F2B103BADB1FD5D"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) is accepting nominations for the 2016 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology.</p><p>The <a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=2">Lloyd J. Old Award in Cancer Immunology</a> was established in 2013 to honor the memory of the late Lloyd J. Old, MD, who is considered the “Father of Modern Tumor Immunology,” and to recognize an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field.</p><p>The recipient of the fourth annual award will receive a $10,000 honorarium and present a 50-minute lecture at the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=63">AACR Annual Meeting 2016</a>, to be held April 16-20, in New Orleans.</p><p>The 2015 award recognized <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=691">Carl H. June, MD</a>, program director of translational research at the Abramson Cancer Center of the University of Pennsylvania in Philadelphia, for his important contributions to cancer immunology, specifically his pioneering efforts related to the development of chimeric antigen receptor (CAR) T-cell therapy. June delivered his award lecture titled, “CAR T Cells&#58; Can We Move Beyond B Cells?”</p><ul><li>Deadline for nominations&#58; Aug. 5, 2015</li><li><a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=2">Review the award information</a>&#160;or contact Monique P. Eversley at <a href="mailto&#58;awards@aacr.org">awards@aacr.org</a> to learn more.</li></ul></div>
Breast Cancer Survivors Gain More Weight Than Cancer-free Women15374957/15/2015 1:03:46 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx744False2015-07-15T04:20:00ZPost-treatment weight gain is implicated in heart disease and other complications<div class="ExternalClassFFA64E4A44F54A489C7CAE59BFC7EE9F"><p>​PHILADELPHIA — Among women with a family history of breast cancer, those diagnosed with breast cancer gained weight at a greater rate compared with cancer-free women of the same age and menopausal status, according to a <a href="http&#58;//cebp.aacrjournals.org/content/early/2015/07/09/1055-9965.EPI-15-0212.abstract" target="_blank">study</a> published in <em>Cancer Epidemiology, Biomarkers &amp; Prevention</em>, a journal of the American Association for Cancer Research.&#160;</p><p> <img src="/PublishingImages/Visvanathan_Kala_150x200.jpg" alt="" style="margin&#58;5px 10px;vertical-align&#58;auto;float&#58;right;" />&quot;Our study showed that women diagnosed with breast cancer and those who received chemotherapy to treat their breast cancer gained more weight within the first five years of diagnosis and treatment than cancer-free women,&quot; said the study's senior author, <a href="http&#58;//www.jhsph.edu/faculty/directory/profile/3969/kala-visvanathan" target="_blank">Kala Visvanathan, MD, MHS</a>, associate professor of epidemiology at the <a href="http&#58;//www.jhsph.edu/" target="_blank">Johns Hopkins Bloomberg School of Public Health</a> and director of the Clinical Cancer Genetics and Prevention Service at the <a href="http&#58;//www.hopkinsmedicine.org/kimmel_cancer_center/" target="_blank">Sidney Kimmel Comprehensive Cancer Center</a> in Baltimore.</p><p>Of the women treated with chemotherapy within the past five years, 21 percent gained at least 11 pounds over follow-up. &quot;This is of concern because weight gain of this magnitude in adults has been associated with increased future risk for chronic diseases like coronary heart disease, hypertension, and type 2 diabetes,&quot; said the paper's first author, Amy Gross, MHS, doctoral candidate in the department of epidemiology at Bloomberg School of Public Health.</p><p>&quot;This study highlights the need for physicians and their patients, including those with a family history of the disease, to pay closer attention to weight gain during and after treatment,&quot; Visvanathan said.</p><p>Visvanathan and colleagues recruited 303 breast cancer survivors and 307 age- and menopausal status-matched, cancer-free women from the <a href="http&#58;//www.hopkinsmedicine.org/breast_center/treatments_services/breast_cancer_diagnosis/breast_ovarian_surveillance_service_genetic_testing/" target="_blank">Breast and Ovarian Surveillance Service</a> cohort study, which comprises women with familial risk for breast and ovarian cancer, including BRCA1/2 mutation carriers. Eligible study participants were those who had completed a baseline questionnaire (the time point referred to as T1) and at least one follow-up questionnaire (administered every three or four years). Weight gain was computed using data from T1 and follow-up questionnaires.</p><p>The researchers found that survivors who were diagnosed with breast cancer within five years before T1 had gained an average of 3.81 pounds more than cancer-free women. Survivors who were diagnosed with estrogen receptor-negative invasive cancer within five years before T1 had gained an average of 7.26 pounds more than cancer-free women. No significant weight gain was seen among those diagnosed with breast cancer more than five years before T1 or those treated with hormonal therapy for their estrogen receptor-positive cancer.</p><p>Survivors who had received chemotherapy (with or without hormonal therapy) within five years before T1 were more than twice as likely to have gained at least 11 pounds compared with cancer-free women. No significant weight gain was observed in those treated with chemotherapy more than five years before T1.</p><p>&quot;Longer follow-up is needed to confirm the persistence of weight gain in breast cancer survivors and understand the metabolic changes that may be occurring,&quot; Visvanathan cautioned.&#160;</p><p>&quot;We are continuing to follow our study participants to track weight-gain patterns over a longer period of time,&quot; Gross added.&#160;</p><p>Of the 303 breast cancer survivors, 179 had received treatment within five years of T1 and 123 had received treatment more than five years before T1. About 50 percent reported receiving chemotherapy, and about two-thirds reported receiving hormonal therapy. Sixty-eight percent of the breast cancer survivors and 72 percent of the cancer-free women had reported baseline physical activity that met the American Heart Association recommendations.</p><p>This study was funded by the Breast Cancer Research Foundation and the National Institutes of Health. Visvanathan declares no conflicts of interest.</p> </div>
Three Large U.S. Hot Spots Have Excessive Colorectal Cancer Death Rates 14952897/8/2015 2:22:48 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx743False2015-07-08T04:05:00ZMost of the country has seen large decline in disease death rates; data warrant targeted screening intervention<div class="ExternalClassB8908C90FC834816A2A6AE8AAAC4F44C"><p>PHILADELPHIA — While most of the United States has experienced large declines in colorectal cancer death rates in recent years, progress in the Mississippi Delta and two other areas has lagged, according to a <a href="http&#58;//cebp.aacrjournals.org/content/early/2015/06/30/1055-9965.EPI-15-0082.abstract" target="_blank">study</a> published in <em>Cancer Epidemiology, Biomarkers &amp; Prevention</em>, a journal of the American Association for Cancer Research. <a href="/Newsroom/PublishingImages/colorectal-cancer-hot-spots.jpg" target="_blank"><img alt="Colorectal Cancer Hot Spots" src="/PublishingImages/colorectal-cancer-hot-spots_320x247.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></a></p><p>The lower Mississippi Delta, encompassing 94 counties, was identified as the hot spot with the highest colorectal cancer death rates, followed by 107 counties in west central Appalachia, and 37 counties in eastern Virginia/North Carolina.</p><p>“We expanded on an earlier state-level analysis by using a geospatial software tool to identify clusters of counties in the United States that have unnecessarily high colorectal cancer death rates,” said <a href="http&#58;//www.cancer.org/research/acsresearchers/rebecca-siegel-mph" target="_blank">Rebecca Siegel, MPH</a>, director of surveillance information in the Surveillance and Health Services Research Program at the <a href="http&#58;//www.cancer.org/index" target="_blank">American Cancer Society</a> in Atlanta, Georgia.</p><p>“We identified three distinct hot spots—the lower Mississippi Delta, west central Appalachia, and eastern Virginia/North Carolina—where colorectal cancer death rates are elevated compared with most of the country,” Siegel added. “Further, while the rates have begun to decrease in the lower Mississippi Delta for most population groups, they remain stagnant in black men.</p><p>“Although we’ve made great strides against colorectal cancer in a fairly short time period, there are a lot of vulnerable populations that aren’t benefiting. Now that these groups have been identified, there is a moral obligation to do something about it,” Siegel said.</p><p>Siegel explained that over the past few decades we have learned how to prevent most colorectal cancer deaths, which has led to a drop in the U.S. colorectal cancer death rate by half. However, progress has not been equivalent in all states, and large differences exist among states, which she and her colleagues identified in a previous study. For this study, the researchers gathered and analyzed data at a more granular level because targeted interventions are often more feasible on a smaller scale, she said.</p><p>Siegel and colleagues used a geospatial software tool to identify areas of very low rates of colorectal cancer deaths, called cold spots, and areas of very high rates, called hot spots. For areas identified as hot spots, death rates were plotted from 1970 to 2011 and rate ratios were calculated to compare trends over time between hot spots and the rest of the United States.</p><p>Using this spatial mapping, the researchers identified three distinct hot spots. The lower Mississippi Delta hot spot had colorectal cancer death rates that were 40 percent higher than the nonhot spot areas in the country during 2009-2011. Rates in the hot spots in west central Appalachia and eastern Virginia/North Carolina were 18 percent and 9 percent higher, respectively, than those of the nonhot spot areas in the country during this time period.</p><p>The colorectal cancer death rate increased steadily, by 3.5 percent per year, for black men in the lower Mississippi Delta between 1970 and 1990, and has since remained unchanged.</p><p>“These areas are low-hanging fruit for colorectal cancer screening interventions,” Siegel said. “Targeted interventions, like using people within the community to talk to their neighbors about screening, are likely to be effective. We know interventions work because we have an example in Delaware, where they implemented statewide colorectal cancer screening and effectively eliminated disparities in less than a decade.”</p><p>The authors also noted in their paper a crossover of death rates in the lower Mississippi Delta with those in the rest of the United States around 1990&#58; In the early 1970s, death rates in the delta were 18 percent lower than the average death rates in the country.</p><p>This study was funded by the American Cancer Society. Siegel declares no conflicts of interest.</p><p>&#160;</p><p><em>Map courtesy of the American Cancer Society</em></p></div>
​Cancer Today Summer Issue Addresses Financial Strain of Cancer Treatment14566176/30/2015 3:48:03 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx742False2015-06-30T13:00:00Z<div class="ExternalClass3A01E1EC2D0743988850FC5028DC0245"><p>PHILADELPHIA — The Summer 2015 issue of <a href="http&#58;//www.cancertodaymag.org/" target="_blank"><em>Cancer Today</em></a>, a publication of the American Association for Cancer Research (AACR), features “<a href="http&#58;//www.cancertodaymag.org/SUmmer2015/Pages/The-Cost-of-Cancer-Debt-Resources-Help.aspx" target="_blank">The Cost of Cancer</a>,” about how cancer treatments can leave patients and their families heavily in debt. The article also offers resources patients can pursue for financial relief.<a href="http&#58;//www.cancertodaymag.org/" target="_blank"><img alt="Cancer Today Summer 2015 Cover" src="/PublishingImages/Cancer_Today_SUM15_Cover_320x411.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></a></p><p>Published quarterly by the AACR, <em>Cancer Today</em> is an authoritative resource for cancer patients, survivors, and their family members and friends. In every issue, <em>Cancer Today</em> offers information and inspiration to help readers face the challenges of diagnosis, treatment, survivorship, and caregiving.</p><p>This issue of <em>Cancer Today</em> also includes “<a href="http&#58;//www.cancertodaymag.org/SUmmer2015/Pages/Fertility-Preservation-Cancer.aspx" target="_blank">Preserving the Future</a>,” a story about how cancer treatment may affect the ability of young cancer patients to have children, and the steps they can take to preserve their fertility. </p><p>Brain cancer survivor and pediatrician P.J. Lukac <a href="http&#58;//www.cancertodaymag.org/SUmmer2015/Pages/Pediatrician-Glioblastoma-Survivor-P-J-Lukac-Has-Desire-To-Help.aspx" target="_blank">tells how cancer shaped his career path</a>, and “<a href="http&#58;//www.cancertodaymag.org/SUmmer2015/Pages/DCIS-Dilemma-Ductal-Carcinoma-In-Situ-Treatment.aspx" target="_blank">The DCIS Dilemma</a>” describes the tough treatment decisions that women diagnosed with ductal carcinoma in situ often face.</p><p>To read these stories and others, go to <a href="http&#58;//www.cancertodaymag.org/" target="_blank"><em>Cancer Today</em></a>, or follow the magazine on <a href="https&#58;//www.facebook.com/CancerToday" target="_blank">Facebook</a> and <a href="https&#58;//twitter.com/CancerTodayMag" target="_blank">Twitter</a>. </p><p><em>Cancer Today</em> also publishes a free <a href="http&#58;//www.cancertodaymag.org/pages/newsletter-signup.aspx" target="_blank">monthly e-newsletter</a>, which contains links to web exclusives, information about events and resources, and highlights from new issues. </p><p>Media are welcome to use information from <em>Cancer Today</em>; however, we ask that you cite the source.</p></div>
American Association for Cancer Research Journals Receive Top Rankings in 2015 Report14482816/29/2015 6:14:14 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx740False2015-06-29T16:00:00Z<div class="ExternalClass90AF401C71B14CAF87484818931280AC"><p>PHILADELPHIA — The journals of the American Association for Cancer Research (AACR) ranked in the top 30 percent of all oncology journals with regard to Impact Factor, according to the latest <em>Journal Citation Report</em> from Thomson Reuters, the industry-standard measurement report. </p><p>The AACR’s highly cited journals received 17 percent of all citations in the oncology category whereas they represented 6 percent of all articles published in the oncology category. </p><p>Three of the AACR journals—<em>Cancer Discovery</em>, <em>Cancer Research</em>, and <em>Clinical Cancer Research</em>—ranked in the top 6 percent by Impact Factor (of 211 oncology journals measured by Thomson Reuters).</p><p>For the 19th consecutive year, <em>Cancer Research</em> ranked first among oncology journals in the number of total citations, with approximately 143,000. <em>Cancer Research</em> ranked 23rd in total citations among all 8,618 journals measured by Thomson Reuters. </p><p><em>Clinical Cancer Research</em> ranked third in total citations among oncology journals, with more than 72,000 citations. </p><p>“This report shows that the AACR’s eight peer-reviewed journals continue to be an authoritative and respected source of information for researchers from across the world’s cancer research community,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “The outstanding success of our journals is a testament to the expertise and hard work of our authors, scientific editors, and staff. We deeply appreciate all of our colleagues who give so generously of their time and wisdom to ensure the dissemination of the highest-quality innovative cancer science and medicine among scientists. This is a priority for the AACR as it is crucial to accelerating the pace of progress in the prevention and cure of cancer.”</p><p><a href="http&#58;//www.aacrjournals.org/site/Info/impact_factor.xhtml" target="_blank">View</a> the complete journal ranking information. </p><p>The eight journals of the AACR are&#58; <a href="http&#58;//cancerdiscovery.aacrjournals.org/" target="_blank"><em>Cancer Discovery</em></a>; <a href="http&#58;//cebp.aacrjournals.org/" target="_blank"><em>Cancer Epidemiology, Biomarkers &amp; Prevention</em></a>; <a href="http&#58;//cancerimmunolres.aacrjournals.org/" target="_blank"><em>Cancer Immunology Research</em></a>; <a href="http&#58;//cancerres.aacrjournals.org/" target="_blank"><em>Cancer Research</em></a>; <a href="http&#58;//cancerpreventionresearch.aacrjournals.org/" target="_blank"><em>Cancer Prevention Research</em></a>; <a href="http&#58;//clincancerres.aacrjournals.org/" target="_blank"><em>Clinical Cancer Research</em></a>; <a href="http&#58;//mcr.aacrjournals.org/" target="_blank"><em>Molecular Cancer Research</em></a>; and <a href="http&#58;//mct.aacrjournals.org/" target="_blank"><em>Molecular Cancer Therapeutics</em></a>. </p></div>
Cancer Discovery's Impact Factor Rises to 19.453 in 2015 14482736/29/2015 6:13:30 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx741False2015-06-29T15:00:00ZMeasurement of the journal's impact has increased 92 percent in just two years<div class="ExternalClass52D08D85452C4D25A2C549DCF6D27501"><p>PHILADELPHIA — <em>Cancer Discovery</em>, a journal of the American Association for Cancer Research (AACR), reported an Impact Factor of 19.453 in 2015, which is a 22 percent increase over the 15.929 Impact Factor from 2014 and a 92 percent increase over the 10.143 Impact Factor from 2013.</p><p>The journal ranked fifth out of 211 oncology journals, according to the latest <em>Journal Citation Report</em> from Thomson Reuters, the industry standard for journal impact measurement. It ranked third in regard to the Immediacy Index, which indicates how quickly an article is cited.</p><p><em>Cancer Discovery</em> is co-led by editors-in-chief Lewis C. Cantley, PhD, director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College in New York, and José Baselga, MD, PhD, president of the AACR and physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center in New York.</p><p>“The AACR is thrilled that the <em>Cancer Discovery</em> Impact Factor has increased significantly yet again this year,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “We applaud the vision and hard work of Drs. Cantley and Baselga, the editors-in-chief of the journal, as well as our expert scientific editors of the journal’s editorial board and the many authors whose outstanding papers we have published. Clearly, under the direction of the editors-in-chief, we are providing an important resource to cancer researchers around the world that presents the most compelling and innovative cancer science and medicine in the cancer field.” </p><p><em>Cancer Discovery</em> publishes high-impact, peer-reviewed articles describing major advances in basic, translational, and clinical research, as well as cancer science news, review articles, perspectives, commentaries, and summaries of other important peer-reviewed journal articles.</p><p><em><a href="http&#58;//cancerdiscovery.aacrjournals.org/" target="_blank">Cancer Discovery</a></em> is one of eight journals published by the AACR. The other journals are <a href="http&#58;//cebp.aacrjournals.org/" target="_blank"><em>Cancer Epidemiology, Biomarkers &amp; Prevention</em></a>; <a href="http&#58;//cancerimmunolres.aacrjournals.org/" target="_blank"><em>Cancer Immunology Research</em></a>; <a href="http&#58;//cancerpreventionresearch.aacrjournals.org/" target="_blank"><em>Cancer Prevention Research</em></a>; <a href="http&#58;//cancerres.aacrjournals.org/" target="_blank"><em>Cancer Research</em></a>; <a href="http&#58;//clincancerres.aacrjournals.org/" target="_blank"><em>Clinical Cancer Research</em></a>; <a href="http&#58;//mcr.aacrjournals.org/" target="_blank"><em>Molecular Cancer Research</em></a>; and <a href="http&#58;//mct.aacrjournals.org/" target="_blank"><em>Molecular Cancer Therapeutics</em></a>.</p><p>Read more information on <a href="http&#58;//cancerdiscovery.aacrjournals.org/" target="_blank"><em>Cancer Discovery</em></a>. </p></div>
AACR Launches New Funding Initiative to Promote Innovative Research From Young Investigators103376/25/2015 2:30:47 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx739False2015-06-25T14:30:00ZLetters of Intent for the NextGen Grants for Transformative Cancer Research are due Aug. 10<div class="ExternalClassCD0202C695D44FBEB572899FB0B1EA61"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) is pleased to announce the launch of the <a href="/Funding/Pages/Funding-Detail.aspx?ItemID=48">AACR NextGen Grants for Transformative Cancer Research</a>, a new funding initiative to stimulate highly innovative research from young investigators.</p><p>This new grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that, because of its very nature, may not otherwise be funded through existing channels. It is expected that these grants will catalyze significant scientific discoveries and help talented young investigators gain scientific independence.</p><p>“The AACR NextGen Grants for Transformative Cancer Research represent an exciting new initiative to provide funding to young investigators who are working on projects that have the potential to lead to major breakthroughs in the field of cancer research,” said Carlos L. Arteaga, MD, AACR immediate past-president, and the Donna S. Hall chair in breast cancer research and director of the Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. “Young investigators are vital to our future progress against cancer because they are the source of many of the most novel, ambitious, and transformative ideas in cancer research. We at the AACR are proud to be able to offer them this mechanism of support.”</p><p>“The American Association for Cancer Research is thrilled to offer this new funding opportunity to support the work of promising young investigators,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “We are in the midst of a serious crisis in funding for biomedical research, and early-career researchers are particularly vulnerable when funding stagnates or declines. The AACR is committed to sustaining the pipeline of young investigators, and strengthening the support for these individuals is essential if we are to continue to make advances that lead to patient benefits.”</p><p>Eligibility will be limited to junior faculty who, at the start of the grant term, have held a full-time, tenure-track appointment as an assistant professor for no more than three years. The proposed research must represent a highly innovative approach to a major contemporary challenge in cancer research. The funded projects must have the potential to lead to groundbreaking discoveries in the field, and transform our understanding of the tumorigenesis process and/or our ability to treat, detect, or prevent cancer. The research can be in any area of basic, translational, or clinical science.</p><p>The grants will provide a total of $450,000 over a period of three years, beginning July 1, 2016. The recipients will formally accept the grants at the AACR Annual Meeting 2016, held April 16-20, in New Orleans.</p><p>Further details are <a href="/Funding/Pages/Funding-Detail.aspx?ItemID=48">available online</a>. Letters of intent must be submitted by noon ET, Aug. 10, 2015, using the <a href="https&#58;//proposalcentral.altum.com/" target="_blank">proposalCENTRAL website</a>. Additional inquiries may be directed to Ashley Jones at <a href="mailto&#58;grants@aacr.org">grants@aacr.org</a>.</p></div>
Blood Antibodies May Predict HPV-positive Oropharyngeal Cancer Survival103356/15/2015 1:15:02 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx737False2015-06-15T04:05:00Z<div class="ExternalClass027CD674F416477BA3B0A91BFE18340E"><p>PHILADELPHIA — The presence of certain human papillomavirus (HPV)-16 antibodies in the blood was associated with improved rates of survival among patients with HPV-related oropharyngeal carcinoma, according to a <a href="http&#58;//clincancerres.aacrjournals.org/content/21/12/2861.abstract" target="_blank">study</a> published in <em>Clinical Cancer Research</em>, a journal of the American Association for Cancer Research. This study implies that antibody positivity may help identify those patients with HPV-positive tumors who could benefit from altered monitoring or treatments.</p><p>“We found that patients who were serologically positive to the E proteins of HPV16 had a better prognosis than those patients who were seronegative to these antigens,” said study author <a href="http&#58;//faculty.mdanderson.org/Erich_Sturgis/" target="_blank">Erich M. Sturgis, MD, MPH</a>, professor in the Department of Head and Neck Surgery at <a href="http&#58;//www.mdanderson.org/" target="_blank">The University of Texas MD Anderson Cancer Center</a>. “This seemed particularly true of patients who had tumors that we could confirm were HPV-positive.”</p><p>According to Sturgis, the incidence of HPV-positive oropharyngeal carcinoma has increased dramatically in recent years. Although patients with HPV-positive disease have a better prognosis than those with HPV-negative disease, researchers are still seeking a better understanding of what group of patients is more likely to respond to treatment.</p><p>In this study, Sturgis and colleagues used blood samples from 209 patients with previously untreated oropharyngeal carcinoma, including 96 who had confirmed HPV-positive disease, and screened the samples for HPV16 antibodies E1, E4-7, L1, L2, and the N-terminal and C-terminal fragments of E2. Samples were taken as part of the initial patient workup, six weeks after the end of treatment, and at six-month intervals up to three years.</p><p>Patients who were positive for any of the E antibodies tested had improved overall and progression-free survival compared with those negative for the antibodies.</p><p>The five-year overall survival estimate for patients positive for E antibodies was 87.4 percent compared with 42.2 percent for patients negative for E antibodies. The five-year progression-free survival estimate was 82.9 percent for antibody-positive patients compared with 46.1 percent for antibody-negative patients.</p><p>Patients with HPV-positive disease who were also positive for the NE2, E1, or E6 antibodies had an 80 percent reduced risk for death and a 70 percent reduced risk for disease progression.<br>No survival advantage was noted for the L antibodies tested in the study.</p><p>E proteins of HPV are antigens that play a role in HPV-mediated carcinogenesis, and L proteins are involved in the development of the virus shell, which are lost once the HPV DNA is integrated into human DNA, Sturgis explained.</p><p>“If this testing became commercially available it could not only be used as a means of identifying people who are at risk for oropharyngeal and other HPV cancers, but may also allow identification of HPV-related oropharyngeal cancer patients at greater or lower risk for cancer recurrence and death. These data further suggest that if we can modify patient immunity and increase a patient’s E antibody response, we might be able to affect cancer outcomes,” Sturgis said. “Clinical trials are now testing whether vaccines that can stimulate these antibodies have clinical utility in HPV-related cancers.”</p><p>This study was funded by the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Arizona State University institutional funds, the National Cancer Institute Early Detection Research Network, and the Stiefel Oropharyngeal Research Fund. Sturgis declares no conflicts of interest.</p></div>
ALK1 Protein May Play a Role in Breast Cancer Metastasis103366/15/2015 1:19:08 PMhttp://www.aacr.org/Newsroom/Lists/News Releases/AllItems.aspx738False2015-06-15T04:05:00ZAn investigational drug targeting ALK1 prevented disease spread in preclinical studies<div class="ExternalClass22374A68B6084877A3F62EE76DC39B5F"><p>​PHILADELPHIA — Breast cancer patients with high levels of the protein activin-like receptor kinase (ALK1) in the blood vessels of their tumors were more likely to develop metastatic disease, according to a <a href="http&#58;//cancerres.aacrjournals.org/content/75/12/2445.abstract" target="_blank">study</a> published in <em>Cancer Research</em>, a journal of the American Association for Cancer Research. <img alt="Kristian Pietras, PhD" src="/PublishingImages/Pietras_Kristian_150x200.jpg" style="margin&#58;5px 10px;vertical-align&#58;auto;float&#58;right;" /></p><p>This makes inhibition of the ALK1 pathway a possible new target for the treatment of metastatic breast cancer.</p><p>“Although prognosis for breast cancer is relatively good when detected in its early stages, metastatic disease is the cause of 90 percent of all cancer-related deaths. Therefore, learning more about the metastatic process and finding new cures to inhibit disease spread is at the center of clinical attention,” said <a href="http&#58;//ki.se/en/mbb/kristian-pietras-group" target="_blank">Kristian Pietras, PhD</a>, the Goran and Birgitta Grosskopf professor of molecular medicine at <a href="http&#58;//www.lunduniversity.lu.se/" target="_blank">Lund University</a>. </p><p>“We are investigating the role of ALK1 protein expressed by endothelial cells in promoting metastatic dissemination from primary breast tumors,” Pietras said.</p><p>Pietras explained that in order for a tumor to spread, a cancer cell must detach and traverse the vascular wall to escape into the blood stream, exit the vasculature to enter the metastatic site, and colonize the new tissue. The fact that the process of escape into and from the vasculature is regulated implies that it is possible to use drugs to block this process, he said.</p><p>“Our results suggest that the presence of high levels of ALK1 in the breast tumor vasculature is a prognostic biomarker for metastatic disease,” Pietras added. “Moreover, our work encourages clinical testing of drugs blocking ALK1 in breast cancer with prevention of metastatic dissemination as the primary outcome.”</p><p>Using multiple mouse models of breast cancer, Pietras and colleagues found that a mouse version of the ALK1 inhibitor dalantercept prevented metastatic dissemination and that combination therapy with dalantercept and the chemotherapy docetaxel was effective in preventing the spread of the primary breast tumor to the lungs.<br>&#160;<br>Next, the researchers analyzed gene-expression patterns in tumors from 768 patients in a population-based, nested case-control study. This analysis showed that expression of ALK1 was significantly associated with the incidence of metastatic disease. In order to further validate their findings, Pietras and colleagues analyzed breast cancer gene-expression data from The Cancer Genome Atlas and found that ALK1 expression correlated with the expression of well-known endothelial markers and that higher levels of ALK1 expression were an independent prognostic factor for poor survival in breast cancer patients.</p><p>“We are currently performing therapeutic studies with dalantercept in models of breast cancer in order to pinpoint the precise therapeutic regimen and disease stage at which the treatment is the most effective,” Pietras said.</p><p>This study was funded by the European Research Council; the Swedish Research Council; the Swedish Cancer Society; the STARGET Consortium; BioCARE; Lund University; BRECT; the Karolinska Institutet and Stockholm County Council; and the Radiumhemmet, Karolinska Institutet, and Karolinska University Hospital. Pietras is an inventor on a patent pertaining to ALK1 antagonism held by the Ludwig Institute for Cancer Research Ltd., and licensed to Acceleron Pharma, a company that develops dalantercept for commercial purposes.</p></div>